RE: Grok on early FDA approval20 Aug 2025 15:52
Reposting Energyshares post earlier...excellent bit of info...
'What is the earliest phase FDA drug approval in oncology ?
The earliest phase for FDA drug approval in oncology is typically based on data from Phase 2 clinical trials, though in rare cases, accelerated approval can be granted using data from Phase 1b expansion cohorts combined with early Phase 2 studies. The FDA’s accelerated approval pathway allows approval for drugs treating serious conditions with unmet medical needs based on surrogate endpoints (e.g., response rate or disease control rate) rather than definitive endpoints like overall survival, which are usually required for full approval from Phase 3 trials. However, approvals solely based on Phase 1b data are exceptionally rare and usually involve compelling evidence from larger, well-designed expansion cohorts in diseases with no standard treatments.
A notable example is larotrectinib (Vitrakvi), approved in 2018 for NTRK gene fusion-positive tumors, a rare cancer. The FDA granted accelerated approval based on data from a Phase 1 trial, a Phase 1/2 pediatric trial, and a Phase 2 basket trial, collectively involving 55 patients. The overall response rate was 75%, with no Phase 3 data required due to the rarity of the condition and lack of alternative therapies. This is one of the earliest-phase approvals in oncology, leveraging combined Phase 1 and 2 data.
For context, Phase 1 trials (including 1b) focus on safety, dosing, and preliminary efficacy in small groups (20-100 patients), making them insufficient alone for approval without exceptional circumstances. Even in accelerated approvals, the FDA typically requires confirmatory trials post-approval to verify clinical benefit. For rare cancers like salivary gland cancer, approvals often follow similar patterns, but Phase 1b data alone, such as the 91% disease control rate for AVA6000, would not suffice without further Phase 2 or confirmatory data.
So looks like we need some phase 2 data.'
Sign In
Follow the stocks
